BWM
JUNO

Baystate Wealth Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Baystate Wealth Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100
Closed -$3K – 714
2017
Q2 		$3K Hold
100
– – ﹤0.01% 472
2017
Q1 		$2K Hold
100
– – ﹤0.01% 492
2016
Q4 		$2K Buy
+100
New +$2.45K ﹤0.01% 406

Other funds holding JUNO

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Baystate Wealth Management's JUNO Position: Q3 2017 in Review

Baystate Wealth Management sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2017, closing a stake of 100 shares — an estimated $3K sold.

Baystate Wealth Management first reported a position in JUNO in Q4 2016 and held it in 3 quarters. The position peaked at $3K in Q2 2017. 210 funds tracked by Wall St. Rank hold JUNO as of Q3 2017.

  • Baystate Wealth Management reported no remaining Juno Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Baystate Wealth Management sold 100 Juno Therapeutics, Inc. shares in Q3 2017, an estimated $3K.
  • Baystate Wealth Management first reported a position in Juno Therapeutics, Inc. in Q4 2016 and held it in 3 quarters.
  • Baystate Wealth Management's Juno Therapeutics, Inc. position peaked at $3K in Q2 2017.
  • 210 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2017.

Based on Baystate Wealth Management's 13F filing for Q3 2017, filed 10 Oct 2017.